Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27499 | 0.89 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL1821303 | 0.89 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL29354115 | 0.89 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL7058506 | 0.88 | ESR1 (0.98) | ESR1ESR2 | |
| SCHEMBL7056486 | 0.88 | ESR1 (0.91) | ESR1ESR2 | |
| SCHEMBL7056839 | 0.86 | ESR1 (0.94) | ESR1ESR2 | |
| SCHEMBL2898159 | 0.86 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL6259524 | 0.86 | ESR1 (0.84) | ESR1ESR2 | |
| SCHEMBL21571869 | 0.84 | ESR1 (0.83) | ESR1ESR2 | |
| SCHEMBL28107129 | 0.83 | ESR1 (0.84) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058774-A1 | SEX STEROID PRECURSORS ALONE OR IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE PREVENTION AND TREATMENT OF DYSPAREUNIA IN POSTMENOPAUSAL WOMEN | ENDORECHERCHE, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20110312925-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | ENDORECHERCHE, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058774-A1 | SEX STEROID PRECURSORS ALONE OR IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE PREVENTION AND TREATMENT OF DYSPAREUNIA IN POSTMENOPAUSAL WOMEN | GPER1, ESR1, ESR2 | ESR1 2/4885ESR2 3/4885 |
| US-20110312925-A1 | METHODS OF TREATING OR PREVENTING ESTROGEN-RELATED DISEASES | SHBG, ESRRA, ESR2 | ESR1 8/4885ESR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.